Report adverse event
FAQ
Log In/Register
International
Bulgaria
CZECH REPUBLIC
Denmark
Finland
Latvia
Moldova
Netherlands
Norway
Poland
Romania
Russia
Serbia
Slovakia
Slovenia
Spain
Sweden
Ukraine
Switzerland
Austria
Asean
About schizophrenia
Log in required
Local regulations restrict this content to healthcare professionals
<a href="https://login.doccheck.com/code/com/2000000013340/l_red/"target="_blank">Login</a>
What is Schizophrenia?
Neurochemical basis of schizophrenia
What are negative symptoms?
The Challenge of Negative Symptoms in Schizophrenia
Diagnosis of schizophrenia
Diagnostic Tools
Diagnostic Tools
The Challenge of Diagnosing Negative Symptoms
Transdiagnostic tool
Treatment of schizophrenia
Burden of schizophrenia and negative symptoms
Log in required
Local regulations restrict this content to healthcare professionals
<a href="https://login.doccheck.com/code/com/2000000013340/l_red/" target="_blank">Login</a>
<a href="https://login.doccheck.com/code/com/2000000013340/l_red/" target="_blank">Login</a>
Treating Negative Symptoms of Schizophrenia
Our Product
Log in required
Local regulations restrict this content to healthcare professionals
<a href="https://login.doccheck.com/code/com/2000000013340/l_red/"target="_blank">Login</a>
Log in required
Local regulations restrict this content to healthcare professionals
<a href="https://login.doccheck.com/code/com/2000000013340/l_red/" target="_blank">Login</a>
<a href="https://login.doccheck.com/code/com/2000000013340/l_red/" target="_blank">Login</a>
Mode of Action
The Mechanism of Action of Our Product
Log in required
Local regulations restrict this content to healthcare professionals
<a href="https://login.doccheck.com/code/com/2000000013340/l_red/" target="_blank">Login</a>
<a href="https://login.doccheck.com/code/com/2000000013340/l_red/" target="_blank">Login</a>
Clinical Data
Efficacy
Our Product in patients with acute exacerbation of schizophrenia
Cariprazine in the Long-Term Treatment of Schizophrenia
Cariprazine Controls Negative Symptoms in Schizophrenia
Controlling Everyday Functioning with Cariprazine
Cariprazine's Effects on Primary and Secondary Negative Symptoms: The Pseudospecificity Problem
Safety
Akathisia Guide
The Safety and Tolerability Profile of Our Product
The Management of Akathisia
Our product and Weight Gain
Log in required
Local regulations restrict this content to healthcare professionals
<a href="https://login.doccheck.com/code/com/2000000013340/l_red/" target="_blank">Login</a>
<a href="https://login.doccheck.com/code/com/2000000013340/l_red/" target="_blank">Login</a>
Prescribing Our Product
Initiating
Switching
Dosing
Cariprazine Dosing Guide
Polypharmacy
Polipharmacy Guide
Experience our product
Log in required
Local regulations restrict this content to healthcare professionals
<a href="https://login.doccheck.com/code/com/2000000013340/l_red/"target="_blank">Login</a>
Reagila Patients
PATIENT SERIES: ACUTE PATIENTS
PATIENT SERIES: PATIENTS WITH NEGATIVE SYMPTOMS
PATIENT SERIES: THE SUBACUTE PATIENT
PATIENT SERIES: PATIENTS WITH THERAPEUTIC COMPROMISE – LACK OF EFFICACY
PATIENT SERIES: PATIENTS WITH THERAPEUTIC COMPROMISE – SAFETY ISSUES
Log in required
Local regulations restrict this content to healthcare professionals
<a href="https://login.doccheck.com/code/com/2000000013340/l_red/" target="_blank">Login</a>
<a href="https://login.doccheck.com/code/com/2000000013340/l_red/" target="_blank">Login</a>
Patient cases
A clinical case of patient with early psychosis treated with cariprazine
Our product add-on in inadequate clozapine response: a case study
Case Study of a Drug-Naïve Female Patient Treated With Cariprazine
Our product add-on in inadequate clozapine response: another case study
Early psychosis treated with cariprazine: a case study
Patient Cases Series
Education & Resources
Log in required
Local regulations restrict this content to healthcare professionals
<a href="https://login.doccheck.com/code/com/2000000013340/l_red/"target="_blank">Login</a>
Interviews & video materials
Antagonist or partial agonist – which one is the best drug?
The role of partial agonists in schizophrenia treatment: managing the clinical aspects - ECNP 2020
Treatment with our product to address schizophrenia needs - ECNP 2020
Scientific Article Summaries
Literature Review
Schizophrenia: negative symptoms
Cariprazine in the treatment of schizophrenia in clinical research and the real-world
The safety of recently developed antipsychotics
Dose-response in antipsychotics
Dosing antipsychotics in acute schizophrenia
Clinical guide for treating negative symptoms in schizophrenia
A skizofrénia negatív tüneti dimenzióinak patofiziológiai megértése
Validation of the PANSS in two-factor negative symptom distinction
Benefits of Antipsychotic Polypharmacy in Schizophrenia Maintenance Therapy
Schizophrenia: Is It All Down To Your Genes?
Causal Relationship Between Cognitive Deficit and Risk of Schizophrenia
Connection Between Inflammation and Schizophrenia?
Potential benefits of using eHealth in the management of schizophrenia
Markers of Inflammation and Infection in Schizophrenia
The Role of Cannabis in Treatment-Resistant Schizophrenia
Childhood Behaviour to Predict Psychosis-Spectrum Diagnoses in Adulthood
Suicide Prevention
Investigating the Stigma Around Mental Health and When People Seek Professional Advice to Control Early Psychiatric Symptoms
Reversal of Schizophrenia Memory Deficits
Switching Antipsychotic Medications in Schizophrenia: Why, When and How?
Can Substance Abuse Cause Psychosis?
The Epstein–Barr Virus and Schizophrenia
Antipsychotic polypharmacy and non-adherence
How to provide care for people with schizophrenia: challenges posed by the covid-19 pandemic
Biomarker Signature of Negative Symptoms
The hyperacute schizophrenic patient
How physical exercise helps individuals with schizophrenia
COVID-19 and mental health
COVID-19 and suicidality
COVID-19 and the risk of developing mental health problems
COVID-19 and schizophrenia
Association between COVID-19 and psychiatric illnesses – a summary of different articles
Downloadable
Akathisia Guide
Cariprazine Dosing Guide
Polipharmacy Guide
Dual Disorder Guide
Transdiagnostic tool
pen-and-paper version
The Candid Book
Understanding the Dimensions of Schizophrenia
Psychiatrist’s view: What are the dimensions of schizophrenia?
Events
Log in required
Local regulations restrict this content to healthcare professionals
<a href="https://login.doccheck.com/code/com/2000000013340/l_red/"target="_blank">Login</a>
Latest events
Archive events
Visit this section
About schizophrenia
What is Schizophrenia?
Neurochemical basis of schizophrenia
What are negative symptoms?
The Challenge of Negative Symptoms in Schizophrenia
Diagnosis of schizophrenia
Diagnostic Tools
Diagnostic Tools
The Challenge of Diagnosing Negative Symptoms
Transdiagnostic tool
Treatment of schizophrenia
Burden of schizophrenia and negative symptoms
Treating Negative Symptoms of Schizophrenia
Our Product
Mode of Action
The Mechanism of Action of Our Product
Clinical Data
Efficacy
Our Product in patients with acute exacerbation of schizophrenia
Cariprazine in the Long-Term Treatment of Schizophrenia
Cariprazine Controls Negative Symptoms in Schizophrenia
Controlling Everyday Functioning with Cariprazine
Cariprazine's Effects on Primary and Secondary Negative Symptoms: The Pseudospecificity Problem
Safety
Akathisia Guide
The Safety and Tolerability Profile of Our Product
The Management of Akathisia
Our product and Weight Gain
Prescribing Our Product
Initiating
Switching
Dosing
Cariprazine Dosing Guide
Polypharmacy
Polipharmacy Guide
Experience our product
Reagila Patients
PATIENT SERIES: ACUTE PATIENTS
PATIENT SERIES: PATIENTS WITH NEGATIVE SYMPTOMS
PATIENT SERIES: THE SUBACUTE PATIENT
PATIENT SERIES: PATIENTS WITH THERAPEUTIC COMPROMISE – LACK OF EFFICACY
PATIENT SERIES: PATIENTS WITH THERAPEUTIC COMPROMISE – SAFETY ISSUES
Patient cases
A clinical case of patient with early psychosis treated with cariprazine
Our product add-on in inadequate clozapine response: a case study
Case Study of a Drug-Naïve Female Patient Treated With Cariprazine
Our product add-on in inadequate clozapine response: another case study
Early psychosis treated with cariprazine: a case study
Patient Cases Series
Education & Resources
Interviews & video materials
Antagonist or partial agonist – which one is the best drug?
The role of partial agonists in schizophrenia treatment: managing the clinical aspects - ECNP 2020
Treatment with our product to address schizophrenia needs - ECNP 2020
Scientific Article Summaries
Literature Review
Schizophrenia: negative symptoms
Cariprazine in the treatment of schizophrenia in clinical research and the real-world
The safety of recently developed antipsychotics
Dose-response in antipsychotics
Dosing antipsychotics in acute schizophrenia
Clinical guide for treating negative symptoms in schizophrenia
A skizofrénia negatív tüneti dimenzióinak patofiziológiai megértése
Validation of the PANSS in two-factor negative symptom distinction
Benefits of Antipsychotic Polypharmacy in Schizophrenia Maintenance Therapy
Schizophrenia: Is It All Down To Your Genes?
Causal Relationship Between Cognitive Deficit and Risk of Schizophrenia
Connection Between Inflammation and Schizophrenia?
Potential benefits of using eHealth in the management of schizophrenia
Markers of Inflammation and Infection in Schizophrenia
The Role of Cannabis in Treatment-Resistant Schizophrenia
Childhood Behaviour to Predict Psychosis-Spectrum Diagnoses in Adulthood
Suicide Prevention
Investigating the Stigma Around Mental Health and When People Seek Professional Advice to Control Early Psychiatric Symptoms
Reversal of Schizophrenia Memory Deficits
Switching Antipsychotic Medications in Schizophrenia: Why, When and How?
Can Substance Abuse Cause Psychosis?
The Epstein–Barr Virus and Schizophrenia
Antipsychotic polypharmacy and non-adherence
How to provide care for people with schizophrenia: challenges posed by the covid-19 pandemic
Biomarker Signature of Negative Symptoms
The hyperacute schizophrenic patient
How physical exercise helps individuals with schizophrenia
COVID-19 and mental health
COVID-19 and suicidality
COVID-19 and the risk of developing mental health problems
COVID-19 and schizophrenia
Association between COVID-19 and psychiatric illnesses – a summary of different articles
Downloadable
Akathisia Guide
Cariprazine Dosing Guide
Polipharmacy Guide
Dual Disorder Guide
Transdiagnostic tool
pen-and-paper version
The Candid Book
Understanding the Dimensions of Schizophrenia
Psychiatrist’s view: What are the dimensions of schizophrenia?
Events
Latest events
Archive events
Report adverse event
International
Bulgaria
CZECH REPUBLIC
Denmark
Finland
Latvia
Moldova
Netherlands
Norway
Poland
Romania
Russia
Serbia
Slovakia
Slovenia
Spain
Sweden
Ukraine
Switzerland
Austria
Asean
website for members of the public
Log In | Register
Healthcare professionals
Public
Share
You are now leaving the site and will be re-directed to an external website.
Accept
Cancel
Showing
0
result(s).
Please log in to see
0
more result(s).
